Company news
Rezolute, Inc. news in 2020
Rezolute, Inc.'s news releases, calls and decks from 2020, newest first.
Rezolute Announces Change of Transfer Agent
December 27, 2020
FDA Clears Rezolute’s IND Application for RZ402
December 2, 2020
Rezolute to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 18, 2020
Rezolute Announces $41 Million Private Placement with Leading Investment Firms and Prepares to Imminently Up-list to Nasdaq
October 8, 2020
Rezolute, Inc. Welcomes Pharmaceutical Industry Leader Philippe Fauchet to its Board of Directors
September 9, 2020
Rezolute, Inc. Provides Updates in the Context of the COVID-19 Pandemic: Announces Resumption and US-Expansion of its Phase 2b Study in Congenital Hyperinsulinism
July 26, 2020
Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science
June 14, 2020
Rezolute Receives Rare Pediatric Disease Designation for RZ358, Phase 2b Candidate for the Treatment of Congenital Hyperinsulinism, Enabling Eligibility for Priority Review Voucher
June 9, 2020
Rezolute Presents RZ358 Clinical Data-Validated Model of the Pharmacokinetics and Glycemic Response in Congenital Hyperinsulinism at Pediatric Endocrine Society 2020 Annual Meeting
May 31, 2020
Rezolute to Present Clinical Data for RZ358, Lead Candidate in Phase 2b Trial in Congenital Hyperinsulinism at Virtual Pediatric Endocrine Society 2020 Annual Meeting
May 27, 2020
Rezolute, Inc. Announces Updates to Clinical and Business Operations in Response to COVID-19 Pandemic
May 13, 2020
Rezolute Initiates Phase 2b Clinical Trial of Lead Candidate RZ358 in Congenital Hyperinsulinism
February 9, 2020
Rezolute to Present at BIO CEO & Investor Conference 2020
January 26, 2020
Decks in 2020
- Technical Presentation (May 2020)
Technical · 14 slides · May 30, 2020